Vitamin D3 for Life

Live Enlightened

Article

Cellular uptake and intracellular handling of vitamin D metabolites: Full Evidence Review

Previous related pageCellular degradation and feedback regulation of vitamin D: Study SummaryNext related pageCellular uptake and intracellular handling of vitamin D metabolites: Study Summary
Study at a glance

How do forms of vitamin D get inside cells?

This review asks how forms of vitamin D reach the inside of cells. In the blood, these forms of vitamin D are mostly attached to vitamin D-binding protein, a carrier. Some cells take in these attached forms using surface proteins called megalin and cubilin. Other ways into cells depend on forms of vitamin D that are not attached to the carrier. The review combines animal experiments, cell studies and observations in kidney disease.

How do kidney cells recover vitamin D that could be lost in urine?

Cells in the kidney’s small filtering tubes recover forms of vitamin D attached to their carrier protein that would otherwise be lost in urine. This both saves vitamin D and supplies material for activation inside the cells. In an animal experiment where megalin was missing, blood 25-hydroxyvitamin D fell by about 80%. This illustrates the importance of the recovery system in that experimental setting.

Do all cells take in vitamin D in the same way?

No. Some tissues outside the kidneys took in vitamin D through these surface proteins. However, this differed between cell types and stages of cell development. Finding a surface protein alone does not prove that it takes in vitamin D. Routes using unattached forms of vitamin D remain important, so carrier uptake is not a universal explanation for every cell.

What remains uncertain about vitamin D entry into cells in kidney disease?

Vitamin D uptake through megalin in the parathyroid glands has not been adequately tested. Kidney-disease studies report conflicting changes in uptake proteins and changes in enzymes that may make up for these differences. A proposed cycle linking low active vitamin D, reduced megalin and poorer activation remains a possible explanation that has not been proven. The findings cannot be assumed to describe every tissue or person with kidney disease.

Read the full article below ↓

Before vitamin D can be activated or degraded inside a cell, its metabolites must first become available to that cell. That requirement sounds simple, but the review by Khan and colleagues shows that substrate access is itself a regulated and tissue-dependent part of vitamin D physiology. Circulating 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)2D] are carried predominantly by vitamin D-binding protein (DBP). Because DBP binds 25(OH)D particularly strongly, the protein-bound pool is large while the freely circulating fraction is very small. The review places free 25(OH)D at roughly 10 pM and free 1,25(OH)2D at roughly 1 pM, representing less than 0.1% and about 1% of their respective circulating concentrations. Cellular vitamin D metabolism therefore depends not only on enzyme expression, but also on how a particular cell gains access to a largely protein-bound extracellular reservoir.

The best-established solution occurs in the renal proximal tubule, where the endocytic receptor megalin works with cubilin, amnionless and intracellular adaptor proteins to retrieve DBP-bound vitamin D metabolites from tubular fluid. Outside the kidney, however, the evidence is more heterogeneous. Some tissues and cell states show functional receptor-mediated uptake, while others remain compatible with access by free or bioavailable metabolites. The scientific question is therefore not whether one transport mechanism replaces all others, but how receptor-mediated uptake, free-metabolite access and intracellular enzyme systems combine differently across tissues.

Why DBP binding makes cellular access a biological problem

DBP is a high-capacity transport protein rather than a passive background carrier. Its affinity for 25(OH)D means that almost all circulating precursor is protein-bound, while its lower affinity for 1,25(OH)2D still leaves most active hormone associated with DBP because DBP itself is abundant. This creates an apparent paradox: many cells express vitamin D-metabolising enzymes, yet most extracellular substrate is not freely dissolved. The review uses this problem to frame two non-exclusive routes. The free-hormone model allows unbound metabolites to cross into target cells, whereas megalin/cubilin-mediated endocytosis provides a way for selected cells to internalise DBP-bound cargo.

The existence of a protein-bound reservoir is important because total circulating concentration and intracellular substrate availability are not identical quantities. A tissue with effective DBP-receptor uptake can draw from a pool that is largely inaccessible to a tissue lacking that machinery. Conversely, strong DBP binding can restrict access where cells depend mainly on the free fraction. This distinction is central to interpreting local vitamin D metabolism: a blood concentration does not by itself specify how much 25(OH)D reaches CYP27B1 or CYP24A1 inside a particular cell.

Megalin, cubilin and the endocytic machinery

Megalin is a large multiligand endocytic receptor with an extracellular ligand-binding region and a cytoplasmic tail containing motifs that recruit adaptor proteins involved in endocytosis and receptor trafficking. The review highlights interactions with proteins including Dab2, AP-2, clathrin, ARH and GIPC. Cubilin is a second DBP-binding receptor that closely cooperates and colocalises with megalin. Because cubilin lacks its own transmembrane domain and cytoplasmic tail, it is anchored through amnionless and works within a receptor complex rather than acting as an independent internalisation system.

This architecture matters mechanistically. It separates ligand recognition from intracellular trafficking and helps explain why loss of one component can disturb uptake even when other components remain present. It also cautions against using the word “megalin” as shorthand for a single-molecule transporter. The physiological route is an endocytic system involving receptor cooperation, adaptor recruitment, vesicle trafficking and intracellular release of cargo.

Cubilin adds measurable ligand capture and physiological dependence

The review gives quantitative support for treating cubilin as a functional partner rather than a descriptive colocalisation marker. DBP binds purified cubilin and megalin in a calcium-dependent manner with similar reported dissociation constants, about 110 ± 15 nM for cubilin and 120 ± 27 nM for megalin. Cubilin can therefore sequester DBP-containing cargo at the cell surface while megalin promotes internalisation of the ligand complex.

Natural and experimental disruption strengthens that interpretation. Dogs with impaired cubilin biosynthesis showed reduced, but not abolished, DBP endocytosis and circulating 25(OH)D and 1,25(OH)2D concentrations approximately 50% below those of unaffected animals; human cubilin mutations have likewise been associated with abnormal urinary handling of DBP and vitamin D metabolites. The receptor partnership is also regulated: thyroidectomy in rats reduced renal cubilin and its association with megalin, with the association restored by thyroxine treatment. These findings add an important qualification to a megalin-centred account: effective receptor-mediated vitamin D handling depends on a regulated multicomponent endocytic system.

Renal proximal tubules provide the strongest causal evidence

In proximal tubular epithelial cells, filtered DBP-bound vitamin D metabolites are recovered from tubular fluid instead of being lost in urine. Classic megalin-deficiency experiments reviewed by Khan et al. showed urinary DBP only in receptor-deficient animals and loss of renal binding and uptake of endogenous DBP. Receptor-associated protein (RAP), an inhibitor of megalin-mediated endocytosis, reduced renal DBP uptake to about 8.2% of untreated control uptake, leaving most of the material to be excreted. Plasma 25(OH)D fell by roughly 80% in the megalin-deficient setting and severe bone disease accompanied the depletion.

Those findings establish two related renal functions. First, endocytosis conserves circulating vitamin D metabolites by preventing urinary loss. Second, it delivers 25(OH)D to proximal tubular cells that contain mitochondrial CYP27B1, making recovered precursor available for conversion to 1,25(OH)2D. The transport step is therefore functionally coupled to metabolism. The kidney does not merely express an activation enzyme; it has a specialised substrate-retrieval system that feeds that enzyme.

Other knockout work strengthens the interpretation. Megalin deficiency increases urinary loss of several ligands, including DBP and 25(OH)D, alongside other low-molecular-weight proteins and vitamin A transport components. The review also notes that calcium-dependent ligand binding matters: EDTA abolished ligand binding to megalin in experimental work. This gives the receptor system biochemical context and shows why disturbances of mineral physiology can intersect with endocytic handling.

The free-hormone route remains necessary to the model

The renal evidence does not invalidate free-metabolite entry. DBP-null mice retain comparatively preserved calcium homeostasis despite very low circulating vitamin D metabolite concentrations. Their kidneys show compensatory changes in vitamin D enzymes, with CYP27B1 activity increasing and CYP24A1 activity decreasing. These observations are difficult to reconcile with a model in which DBP-mediated endocytosis is the only route by which vitamin D metabolites can reach intracellular machinery.

The more defensible interpretation is a tissue-dependent mixture. Megalin/cubilin uptake is a powerful exception to a simple free-hormone model in the kidney and selected extrarenal tissues, but it is not a universal replacement for free or bioavailable entry. Cells lacking the receptor system can still respond to vitamin D metabolites, and the relative importance of bound versus unbound substrate depends on receptor expression, DBP concentration, differentiation state and local physiology.

Extrarenal evidence shows that uptake changes with cell type and state

The review identifies megalin in a wide range of extrarenal epithelia and calciotropic tissues, but expression by itself is not proof of vitamin D uptake. The most informative studies combine receptor expression with functional perturbation. In mammary epithelial cells, fluorophore-labelled DBP was taken up at 37 °C but not at 4 °C, consistent with an active endocytic process. RAP reduced uptake, and internalised 25(OH)D: DBP was able to drive a CYP24A1 reporter response, connecting receptor-mediated entry to intracellular vitamin D signalling rather than merely showing that a fluorescent protein entered the cell.

Muscle studies add a differentiation-dependent dimension. Differentiated myotubes expressed megalin/cubilin and accumulated labelled 25(OH)D at roughly two: to three-fold higher levels than undifferentiated myoblasts. RAP reduced myotube uptake by 66% over 16 hours. The contrast indicates that cellular state can alter substrate access even within one tissue lineage. Adipocyte models showed a different pattern: pre-adipocytes displayed appreciable uptake and stronger megalin expression, whereas differentiated adipocytes showed little or no comparable uptake. These opposing differentiation patterns argue against a universal rule that maturation either increases or decreases receptor-mediated vitamin D handling.

Human mesenchymal stem-cell evidence provides another mechanistic bridge from uptake to downstream function. Cells with lower megalin expression, and cells in which megalin was reduced by small interfering RNA, showed reduced biosynthesis of 1,25(OH)2D from precursor and impaired 25(OH)D-dependent osteoblastogenic responses, while responses to already-active 1,25(OH)2D were preserved more effectively. In the cited work, 1,25(OH)2D biosynthesis was lower by about 46% in low-megalin cells and by about 23% after megalin silencing relative to the respective controls. This helps distinguish a substrate-entry defect from a downstream inability to respond to active hormone.

Parathyroid megalin illustrates the boundary between plausible and demonstrated mechanisms

The parathyroid gland is scientifically interesting because it expresses megalin, vitamin D-metabolising machinery and calcium-sensing systems in the same physiological setting. Anti-parathyroid antibody experiments targeting megalin made parathyroid cells less responsive to extracellular calcium changes for PTH release, supporting a functional role for megalin in calcium sensing or signalling. Megalin expression is also reduced in pathological parathyroid adenomas and is associated with abnormal calcium regulation.

What has not been demonstrated is equally important. The review states that parathyroid megalin has not been adequately tested as a vitamin D uptake mechanism. It would therefore be an evidential overreach to infer that because megalin is present and functionally relevant to calcium sensing, it necessarily supplies DBP-bound 25(OH)D for local parathyroid vitamin D metabolism. The page must preserve this gap rather than completing the mechanism by plausibility.

Kidney disease exposes both compensation and unresolved causality

Chronic kidney disease provides a natural test of what happens when the renal endocytic system is disturbed. In a partial-nephrectomy rat model, megalin mRNA declined from early in the study and continued to fall, while CYP27B1 increased and CYP24A1 decreased. By week 8, CYP27B1 expression was significantly elevated and VDR expression was reduced. Calcium, phosphate and 1,25(OH)2D were not significantly different from controls during the study, whereas PTH rose substantially. This pattern is compatible with compensation, but it does not prove which compensatory route maintained active hormone.

Other models support reduced megalin expression in kidney disease, including angiotensin-II-associated suppression and a 5/6-nephrectomy model in which renal cortical megalin fell while cubilin remained unchanged. Human biopsies in CKD and Fabry nephropathy have also shown reduced megalin/cubilin expression. Yet the direction is not completely consistent: another nephrectomy rat study reported increased megalin and cubilin protein by qualitative immunohistochemistry. The contradiction is material because it prevents a simple claim that CKD uniformly suppresses the receptor system.

The review also discusses a proposed feedback loop in which 1,25(OH)2D supports megalin expression; declining active hormone in CKD could therefore reduce megalin, impair substrate recovery and further depress activation. That “vicious cycle” is biologically coherent but remains a hypothesis. The evidence supports interaction between vitamin D status and megalin regulation, not a fully closed causal chain in human CKD.

Diabetic nephropathy provides quantitative evidence for impaired handling

Diabetic nephropathy shows a related pattern with useful quantitative detail. In diabetic fatty rats, megalin mRNA fell by about 50% and Dab2 mRNA by about 80%, while cubilin mRNA was unchanged. These changes coincided with increased urinary excretion of DBP, 25(OH)D and 1,25(OH)2D and lower serum concentrations of vitamin D metabolites. Mouse and rat diabetic-nephropathy models similarly report increased urinary DBP and reduced proximal-tubule megalin expression.

Human observations point in the same direction without proving that every patient follows the same mechanism. Increased urinary DBP and megalin in type 1 diabetes tracked with vitamin D deficiency, and urinary full-length megalin in predialysis CKD was negatively associated with serum 25(OH)D, 1,25(OH)2D and 24,25(OH)2D. These associations support impaired receptor-mediated conservation as one contributor to dysregulated vitamin D homeostasis, while retaining the broader CKD limitations and model differences described above.

What intracellular “handling” means in practice

Taken together, the review supports a broader definition of cellular handling than simple membrane crossing. It includes extracellular carrier binding, receptor recognition, cubilin/amnionless cooperation, endocytosis, intracellular trafficking and release, delivery of precursor to enzymes such as CYP27B1, compensatory changes in CYP27B1 and CYP24A1 when uptake is disturbed, and access by free or bioavailable metabolites where receptor-mediated uptake is absent or limited. There are also proposed signalling functions of megalin itself, including interactions between megalin-binding proteins and transcriptional machinery, but the review treats these direct signalling mechanisms as incompletely resolved and they should remain secondary to the established uptake function.

The strongest bounded conclusion is therefore tissue-specific. Renal megalin/cubilin-mediated endocytosis is a well-established mechanism for conserving DBP-bound vitamin D and supplying intracellular substrate. Several extrarenal systems show functional receptor-mediated uptake, sometimes with large differences between cell states, but the evidence is not uniform and should not be generalized to all tissues. Free or bioavailable metabolite access remains biologically necessary to the model, and disease evidence shows both compensatory enzyme responses and unresolved causal questions. Cellular vitamin D metabolism begins with substrate access, but the route into the cell is itself part of the physiology.

This uptake-and-handling evidence explains the substrate-access side of Vitamin D Metabolism at the Cellular Level. Once substrate is available, Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1) and Vitamin D Intracrine Activity describe what can happen inside the cell.

Primary source

Khan SS, Petkovich M, Holden RM, Adams MA. Megalin and Vitamin D Metabolism: Implications in Non-Renal Tissues and Kidney Disease. Nutrients. 2022;14(18):3690. Read the full paper.

The Study Summary condenses the uptake mechanism and its main tissue-boundary evidence for rapid orientation.

Related reading

Original sources

Source

Read the full paper

Khan SS, Petkovich M, Holden RM, Adams MA.

Publication details

Khan SS, Petkovich M, Holden RM, Adams MA. Megalin and Vitamin D Metabolism: Implications in Non-Renal Tissues and Kidney Disease. Nutrients. 2022;14(18):3690. Read the full paper.

Read more →